Hemagglutinin-based polyanhydride nanovaccines against H5N1 infuenza elicit protective virus neutralizing titers and cell-mediated immunity

43Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Abstract: H5N1 avian infuenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cellmediated immunity and provide protection upon lethal challenge. In this work, a recombinant H5 hemagglutinin trimer (H53) was produced and encapsulated into polyanhydride nanoparticles. The studies performed indicated that the recombinant H53 antigen was a robust immunogen. Immunizing mice with H53 encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4+ T cell recall responses in mice. Finally, the H53-based polyanhydride nanovaccine induced protective immunity against a low-pathogenic H5N1 viral challenge. Informatics analyses indicated that mice receiving the nanovaccine formulations and subsequently challenged with virus were similar to naç mice that were not challenged. The current studies provide a basis to further exploit the advantages of polyanhydride nanovaccines in pandemic scenarios.

Cite

CITATION STYLE

APA

Ross, K. A., Lyod, H., Wu, W., Huntimer, L., Ahmed, S., Sambol, A., … Narasimhan, B. (2015). Hemagglutinin-based polyanhydride nanovaccines against H5N1 infuenza elicit protective virus neutralizing titers and cell-mediated immunity. International Journal of Nanomedicine, 10, 229–243. https://doi.org/10.2147/IJN.S72264

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free